Biochemical Characterization of GS-4059 As a Potent and Selective Covalent Irreversible Inhibitor of Bruton's Tyrosine Kinase

被引:3
|
作者
Liclican, Albert [1 ]
Xing, Weimei [1 ]
Serafini, Loredana [1 ]
Wang, Ting [1 ]
Brendza, Kathy [1 ]
Lutz, Justin [1 ]
Ray, Adrian S. [1 ]
Schultz, Brian [1 ]
Sakowicz, Roman [1 ]
Feng, Joy Y. [1 ]
机构
[1] Gilead Sci Inc, Foster City, CA USA
关键词
D O I
10.1182/blood.V128.22.1594.1594
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
1594
引用
下载
收藏
页数:5
相关论文
共 50 条
  • [31] Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
    Nagane, Motoo
    Narita, Yoshitaka
    Mishima, Kazuhiko
    Terui, Yasuhito
    Arakawa, Yoshiki
    Yonezawa, Hajime
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Kitagawa, Junsaku
    Aoi, Arata
    Nishikawa, Ryo
    BLOOD, 2019, 134
  • [32] Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)
    Simon A. Rule
    Guillaume Cartron
    Christopher Fegan
    Franck Morschhauser
    Lingling Han
    Siddhartha Mitra
    Gilles Salles
    Martin J. S. Dyer
    Leukemia, 2020, 34 : 1458 - 1461
  • [33] Efficacy of Abbv-105, a Selective and Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Multiple Models of Inflammation
    Goess, Christian
    Graff, Candace
    Zhang, Ting Ting
    Preston, Gregory
    McCarthy, Richard
    Perham, Matthew
    Loud, Jacqueline
    Harris, Christopher M.
    Murdock, Sara
    Sampson, Erik
    Hoemann, Michael
    Friedman, Michael
    Talanian, Robert
    Edmunds, Jeremy
    Long, Andrew
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [34] Modeling the Binding and Conformational Energetics of a Targeted Covalent Inhibitor to Bruton's Tyrosine Kinase
    Awoonor-Williams, Ernest
    Rowley, Christopher N.
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2021, 61 (10) : 5234 - 5242
  • [35] Discovery of a highly selective BTK inhibitor tirabrutinib(ONO/GS-4059) for B-cell lymphoma and inflammatory diseases
    Yamamoto, Shingo
    Suzuki, Ryo
    Hiramatsu, Atsushi
    Kijima, Hideomi
    Watanabe, Toshihide
    Egashira, Hiromu
    Takai, Shigeyuki
    Terakado, Masahiko
    Ogawa, Seiji
    Ima, Masaki
    Nishiyama, Taihei
    Doi, Issei
    Kurono, Masakuni
    Omi, Rie
    Kayasuga, Kana
    Kusuda, Shinya
    Imagawa, Akira
    Habashita, Hiromu
    Seko, Takuya
    Moriarty, Kevin
    Konteatis, Zenon
    Moffett, Kristofer
    Lee, Younghee
    Chao, Wenchun
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 255
  • [36] Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia
    Ghia, Paolo
    Dlugosz-Danecka, Monika
    Scarfo, Lydia
    Jurczak, Wojciech
    LEUKEMIA & LYMPHOMA, 2021, 62 (05) : 1066 - 1076
  • [37] Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition
    Liclican, Albert
    Serafini, Loredana
    Xing, Weimei
    Czerwieniec, Gregg
    Steiner, Bart
    Wang, Ting
    Brendza, Katherine M.
    Lutz, Justin D.
    Keegan, Kathleen S.
    Ray, Adrian S.
    Schultz, Brian E.
    Sakowicz, Roman
    Feng, Joy Y.
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2020, 1864 (04):
  • [38] Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development
    Crawford, James J. y
    Johnson, Adam R.
    Misner, Dinah L.
    Belmont, Lisa D.
    Castanedo, Georgette
    Choy, Regina
    Coraggio, Melis
    Doug, Liming
    Eigenbrot, Charles
    Erickson, Rebecca
    Ghilardi, Nico
    Hau, Jonathan
    Katewa, Arna
    Kohli, Pawan Bir
    Lee, Wendy
    Lubach, Joseph W.
    McKenzie, Brent S.
    Ortwine, Daniel F.
    Schutt, Leah
    Tay, Suzanne
    Wei, BinQing
    Reif, Karin
    Liu, Lichuan
    Wong, Harvey
    Young, Wendy B.
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (06) : 2227 - 2245
  • [39] Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834
    Young, Wendy B.
    Barbosa, James
    Blomgren, Peter
    Bremer, Meire C.
    Crawford, James J.
    Dambach, Donna
    Gallion, Steve
    Hymowitz, Sarah G.
    Kropf, Jeffrey E.
    Lee, Seung H.
    Liu, Lichuan
    Lubach, Joseph W.
    Macaluso, Jen
    Maciejewski, Pat
    Maurer, Brigitte
    Mitchell, Scott A.
    Ortwine, Daniel F.
    Di Paolo, Julie
    Reif, Karin
    Scheerens, Heleen
    Schmitt, Aaron
    Sowell, C. Gregory
    Wang, Xiaojing
    Wong, Harvey
    Xiong, Jin-Ming
    Xu, Jianjun
    Zhao, Zhongdong
    Currie, Kevin S.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (06) : 1333 - 1337
  • [40] Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)
    Watterson, Scott H.
    Liu, Qingjie
    Bertrand, Myra Beaudoin
    Batt, Douglas G.
    Li, Ling
    Pattoli, Mark A.
    Skala, Stacey
    Cheng, Lihong
    Obermeier, Mary T.
    Moore, Robin
    Yang, Zheng
    Vickery, Rodney
    Elzinga, Paul A.
    Discenza, Lorell
    D'Arienzo, Celia
    Gillooly, Kathleen M.
    Taylor, Tracy L.
    Pulicicchio, Claudine
    Zhang, Yifan
    Heimrich, Elizabeth
    McIntyre, Kim W.
    Ruan, Qian
    Westhouse, Richard A.
    Catlett, Ian M.
    Zheng, Naiyu
    Chaudhry, Charu
    Dai, Jun
    Galella, Michael A.
    Tebben, Andrew J.
    Pokross, Matt
    Li, Jianqing
    Zhao, Rulin
    Smith, Daniel
    Rampulla, Richard
    Allentoff, Alban
    Wallace, Michael A.
    Mathur, Arvind
    Salter-Cid, Luisa
    Macor, John E.
    Carter, Percy H.
    Fura, Aberra
    Burke, James R.
    Tino, Joseph A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (07) : 3228 - 3250